Tuesday 11th June 2019
A core pillar of SRUK’s 5-year research strategy is identifying causes behind the development of Raynaud’s and scleroderma. Here we've explored the current research into the potential epigenetic causes of autoimmune conditions like scleroderma.
Thursday 6th June 2019
Despite the similarity of initial symptoms in primary Raynaud’s phenomenon (PRP) and secondary Raynaud’s phenomenon (SRP), the long-term implications of SRP mean that it is critical for there to be more effective assessments that can accurately specify which of the two a person may have.
Tuesday 4th June 2019
Prolonged exposure to hand-transmitted vibration (HTV) can result in hand-arm vibration syndrome (HAVS). When associated with secondary Raynaud’s, this is called vibration white finger, where there is damage to nerves, blood vessels and joints in the hand.
Thursday 23rd May 2019
Self-management is what an individual can do to manage their condition and to help maintain their wellbeing. How this is approached will differ from person to person, but fundamentally it revolves around making decisions to support a healthy lifestyle, whilst recognising the physical and emotional effects the disease can have.
Thursday 16th May 2019
Here is some insight into John Pauling, Consultant Rheumatologist at the Royal National Hospital for Rheumatic Diseases and Senior Lecturer in the Department of Pharmacy & Pharmacology.
Thursday 2nd May 2019
Here at SRUK, we are strong advocates of people living with Raynaud’s and scleroderma continuing to do the things they enjoy; the benefits of exercise are countless for both physical health as well as mental health.
Thursday 4th April 2019
Many scientific investigations concerning scleroderma focus on uncovering more about the processes that contribute to a person presenting symptoms. This is because if the driving factors behind it are defined, treatments can be applied to this area to limit the progression of the condition, either by blocking biological mechanisms or by obstructing involved molecules.
Friday 22nd March 2019
Dr. Elizabeth Renzoni has been working as a consultant respiratory physician at Royal Brompton Hospital in the ILD Unit and an honorary senior lecturer at Imperial College London since 2006. We spoke to her about her career in research.
Wednesday 20th March 2019
Iloprost is used to treat a range of conditions, such as scleroderma, Raynaud's phenomenon, pulmonary hypertension and other diseases where blood vessels are constricted. By relaxing the blood vessels, it makes it easier for blood to flow through, helping to limit the symptoms.
Thursday 14th March 2019
SRUK recently funded David and his team to investigate factors that contribute to the development of calcinosis in scleroderma patients. Find out more about him in our new Meet the Scientist series.
